Novel insulins: Expanding options in diabetes management

American Journal of Medicine

Volumn 113, Issue 4, 2002, Pages 308-316

  Gerich, John E ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN;

ABSORPTION; AEROSOL; ARTICLE; BOLUS INJECTION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEEDING BEHAVIOR; FOOD; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; BLOOD GLUCOSE; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN;

EID: 0036701596     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01176-2     Document Type: Article

References (59)

1. Reichard P., Nilsson B.Y., Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 329:1993;304-309.
2. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus a randomized prospective 6-year study . Diabetes Res Clin Pract. 28:1995;103-117.
3. Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329:1993;977-986.
4. Abraira C., Colwell J.A., Nuttall F.Q., et al. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care. 18:1995;1113-1123.
5. Rizza R.A., Gerich J.E., Haymond M.W., et al. Control of blood sugar in insulin-dependent diabetes comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion, and intensified conventional insulin therapy . N Engl J Med. 303:1980;1313-1318.
6. Dimitriadis G.D., Gerich J.E. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care. 6:1983;374-377.
7. Patrick A.W., Collier A., Matthews D.M., et al. The importance of the time interval between insulin injection and breakfast in determining postprandial glycaemic control - a comparison between human and porcine insulin. Diabet Med. 5:1988;32-35.
8. Heise T., Heinemann L. Rapid and long-acting analogues as an approach to improve insulin therapy an evidence based medicine assessment . Curr Pharm Des. 14:2001;1303-1325.
9. Bolli G.B. Physiological insulin replacement in type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes. 109:(suppl 2):2001;S317-S332.
10. Patton J.S., Bukar J., Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev. 35:1999;235-247.
11. Bolli G.B., Di Marchi R.D., Park G.D., et al. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia. 42:1999;1151-1167.
12. Slieker L.J., Brooke G.S., Di Marchi R.D., et al. Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia. 40:(suppl 2):1997;S54-S61.
13. Heinemann L., Sinha K., Weyer C., et al. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med. 16:1999;332-338.
14. Lindholm A., McEwen J., Riis A.P. Improved postprandial glycemic control with insulin aspart a randomized double-blind cross-over trial in type 1 diabetes . Diabetes Care. 22:1999;801-805.
15. Cefalu W.T., Skyler J.S., Kourides I.A., et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med. 134:2001;203-207.
16. Di Marchi R.D., Chance R.E., Long H.B., et al. Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I. Horm Res. 41:(suppl 2):1994;93-96.
17. Brems D.N., Alter L.A., Beckage M.J., et al. Altering the association properties of insulin by amino acid replacement. Protein Eng. 5:1992;527-533.
18. Radziuk J.M., Davies J.C., Pye W.S., et al. Bioavailability and bioeffectiveness of subcutaneous human insulin and two of its analogs - LysB28ProB29-human insulin and AspB10LysB28ProB29-human insulin - assessed in a conscious pig model. Diabetes. 46:1997;548-556.
19. Rutledge K.S., Chase H.P., Kligensmith G.J., et al. Effectiveness of postprandial Humalog in toddlers with diabetes. Pediatrics. 100:1997;968-972.
20. Heinemann L., Linkeschova R., Rave K., et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 23:2000;644-649.
21. Lepore M., Pampanelli S., Fanelli C., et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 49:2000;2142-2148.
22. Kurtzhals P., Havelund S., Jonassen I., et al. Albumin binding of insulins acylated with fatty acids characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo . Biochem J. 312:1995;725-731.
23. Kang S., Creagh F.M., Peters J.R., et al. Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9, GluB27; AspB10; AspB28) on meal-related plasma glucose excursions in type I diabetic subjects. Diabetes Care. 14:1991;571-577.
24. 125I-labeled insulin glargine (HOE 901) in healthy men comparison with NPH insulin and the influence of different subcutaneous injection sites . Diabetes Care. 23:2000;813-819.
25. ter Braak E.W., Woodworth J.R., Bianchi R., et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care. 19:1996;1437-1440.
26. Anderson J.H., Brunelle R.L., Koivisto V.A., et al. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group. Clin Ther. 19:1997;62-72.
27. Multicenter Insulin Lispro Study Group, Anderson J.H. Jr, Brunelle R.L., Koivisto V.A., et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes. 46:1997;265-270.
28. Anderson J.H. Jr, Brunelle R.L., Keohane P., et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med. 157:1997;1249-1255.
29. Zinman B., Tildesley H., Chiasson J.L., et al. Insulin lispro in CSII results of a double-blind crossover study . Diabetes. 46:1997;440-443.
30. Melki V., Renard E., Lassmann-Vague V., et al. Improvement of HbA1C and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care. 21:1998;977-982.
31. Akram J., De Verga V. Insulin lispro (Lys(B28), Pro(B29) in the treatment of diabetes during the fasting month of Ramadan. Ramadan Study Group. Diabet Med. 16:1999;861-866.
32. Garg S.K., Anderson J.H., Perry S.V., et al. long-term efficacy of humalog in subjects with type 1 diabetes mellitus. Diabet Med. 16:1999;384-387.
33. Del Sindaco P., Ciofetta M., Lalli C., et al. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus importance of appropriate replacement of basal insulin and time-interval injection-meal . Diabet Med. 15:1998;592-600.
34. Ebeling P., Jansson P.-A., Smith U., et al. Strategies toward improved control during insulin lispro therapy in IDDM importance of basal insulin . Diabetes Care. 20:1997;1287-1289.
35. Lalli C., Ciofetta M., Del Sindaco P., et al. long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care. 22:1999;468-477.
36. German Insulin Lispro/IDDM Study Group, Pfützner A., Küstner E., Forst T., et al. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol Diabetes. 104:1996;25-30.
37. Burge M.R., Castillo K.R., Schade D.S. Meal composition is a determinant of lispro-induced hypoglycemia in IDDM. Diabetes Care. 20:1997;152-155.
38. Bolli G.B. Hypoglycaemia unawareness. Diabetes Metab. 23:(suppl 3):1997;29-35.
39. Guerci B., Meyer L., Salle A., et al. Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. J Clin Endocrinol Metab. 84:1999;2673-2678.
40. Brunelle R.L., Llewelyn J., Anderson J.H. Jr, et al. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care. 21:1998;1726-1731.
41. Colombel A., Murat A., Krempf M., et al. Improvement of blood glucose control in type 1 diabetic patients treated with lispro and multiple NPH injections. Diabet Med. 16:1999;319-324.
42. Home P.D., Lindholm A., Riis A., et al. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus a randomized controlled trial . Diabet Med. 17:2000;262-270.
43. Home P.D., Barriocanal L., Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol. 55:1999;199-203.
44. Hedman C.A., Lindstrom T., Arnqvist H.J. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes. Diabetes Care. 24:2001;1120-1121.
45. Home P.D., Lindholm A., Hylleberg B., Round P. Improved glycemic control with insulin aspart a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group . Diabetes Care. 21:1998;1904-1909.
46. Patton J.S. Review mechanisms of macromolecule absorption by the lungs . Adv Drug Deliv Rev. 19:1996;3-36.
47. Skyler J.S., Cefalu W.T., Kourides I.A., et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus a randomised proof-of-concept study . Lancet. 357:2001;331-335.
48. Elliott R.B., Edgar B.W., Pilcher C.C., et al. Parenteral absorption of insulin from the lung in diabetic children. Aust Paediatr J. 23:1987;293-297.
49. Heinemann L., Traut T., Heise T. Time-action profile of inhaled insulin. Diabet Med. 14:1997;63-72.
50. Laube B.L., Georgopoulos A., Adams G.K. III. Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. JAMA. 269:1993;2106-2109.
51. Binder C., Lauritzen T., Faber O., Pramming S. Insulin pharmacokinetics. Diabetes Care. 7:1984;188-199.
52. White J.R. Jr, Campbell R.K., Hirsch I. Insulin analogues new agents for improving glycemic control . Postgrad Med. 101:1997;58-60.,63-65,70.
53. Barnett A.H., Owens D.R. Insulin analogues. Lancet. 349:1997;47-51.
54. Heinemann L., Richter B. Clinical pharmacology of human insulin. Diabetes Care. 16:(suppl 3):1993;90-100.
55. European Study Group of HOE 901 in Type 1 Diabetes, Pieber T.R., Eugène-Jolchine I., Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care. 23:2000;157-162.
56. Ratner R.E., Hirsch I.B., Neifing J.L., et al. US Study Group of Insulin Glargine in Type 1 Diabetes . Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care. 23:2000;639-643.
57. Raskin P., Klaff L., Bergenstal R., et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care. 23:2000;1666-1671.
58. Yki-Jarvinen H., Dressler A., Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care. 23:2000;1130-1136.
59. Radziuk J., Pye S., Bradley B., et al. Basal activity profiles of NPH and [Nepsilon-palmitoyl Lys (B29)] human insulins in subjects with IDDM. Diabetologia. 41:1998;116-120.